Provided by Tiger Trade Technology Pte. Ltd.

CLIMB BIO INC

17.84
+1.448.78%
Post-market: 17.21-0.6300-3.53%19:30 EDT
Volume:1.20M
Turnover:21.45M
Market Cap:1.02B
PE:-21.37
High:18.33
Open:16.75
Low:16.75
Close:16.40
52wk High:18.33
52wk Low:1.54
Shares:57.26M
Float Shares:41.60M
Volume Ratio:1.10
T/O Rate:2.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8347
EPS(LYR):-0.8974
ROE:-27.10%
ROA:-18.45%
PB:4.26
PE(LYR):-19.88

Loading ...

BRIEF-Climb Bio - Announces Initial Phase 1 Safety Data For CLYM116 - SEC Filing

Reuters
·
Jun 05

Climb Bio - No Serious Adverse Events or Dose Limiting Toxicities Observed for Clym116 in Phase 1 - SEC Filing

THOMSON REUTERS
·
Jun 05

Climb Bio reports initial Phase 1 safety data for CLYM116 in healthy volunteers at ERA 2026

Reuters
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Climb Bio (CLYM) and TransMedics Group (TMDX)

TIPRANKS
·
Jun 02

BRIEF-Climb Bio - Files For Resale Of Up To 11.6 Million Shares Of Common Stock By Selling Stockholders

Reuters
·
May 30

Climb Bio - Files for Resale of up to 11.6 Mln Shares of Common Stock by Selling Stockholders- SEC Filing

THOMSON REUTERS
·
May 30

H.C. Wainwright Sticks to Their Buy Rating for Climb Bio (CLYM)

TIPRANKS
·
May 27

Climb Bio presents initial Phase 1 data for CLYM116 in healthy volunteers at ERA 2026

Reuters
·
May 26

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
May 20

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Climb Bio (CLYM)

TIPRANKS
·
May 15

Climb Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 12

Climb Bio, Inc. : H.c. Wainwright Raises Target Price to $20 From $15

THOMSON REUTERS
·
May 12

Climb Bio Is Maintained at Outperform by Wedbush

Dow Jones
·
May 08

Climb Bio price target raised to $17 from $15 at Wedbush

TIPRANKS
·
May 08

Climb Bio Q1 EPS $(0.20) Beats $(0.29) Estimate

Benzinga Earnings
·
May 07

Climb Bio plans multiple-dose study of budoprutug subcutaneous formulation in autoimmune patients

Reuters
·
May 07

Climb Bio price target raised to $19 from $8 at BTIG

TIPRANKS
·
May 07

Wedbush Adjusts Price Target on Climb Bio to $15 From $14, Maintains Outperform Rating

MT Newswires Live
·
May 06

Analysts Offer Insights on Healthcare Companies: DaVita (DVA), IQVIA Holdings (IQV) and Climb Bio (CLYM)

TIPRANKS
·
May 06

Climb Bio Inc : Leerink Partners Raises Target Price to $15 From $10

THOMSON REUTERS
·
May 06